Previous 10 | Next 10 |
home / stock / nvo / nvo articles
IndiaMART, an online marketplace in India, has reportedly taken action to remove unauthorized listings of Novo Nordisk A/S's (NYSE: N...
Due to the recent achievements of GLP-1s, Goldman Sachs sees significant potential for Eli Lilly And Co (NYSE: LLY), Novo ...
The Novo Nordisk Foundation pledged 1.8 billion Danish crowns ($265 million) toward an initiative to enhance vaccines for respiratory illnesses.&nb...
U.S. employers grappling with mounting expenses linked to covering obesity drugs like Novo Nordisk A/S's (NYSE: NVO) Wegovy and ...
There is growing concern among some type 2 diabetes patients over challenges in obtaining reimbursement for medications like Novo Nordisk A/S&...
Novo Nordisk A/S (NASDAQ: NVO) shares are moving Monday and the Ozempic-maker's stock has gained more than 40% year-to-date. Here's a look ...
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chie...
A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S...
What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administere...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...